||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Abzena Share Discussion Threads
Showing 26 to 44 of 50 messages
|Hopefully get picked up by usual culprits next week that should help drive this further IMO, albeit only back to its IPO pricing at least IMO! gla|
|Yup looks like decent potential here, hopefully this year will see more such deals which is what it is all about IMO.
Gla and DYOR, just the beginning IMO|
|The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.|
|This was 80p in May!!|
|1.3 billion market cap potential within the short term or 12-18 months!! 80 million market cap 15 bagged from her buy and hold that's it!!|
|Over 300 million|
|The value of the agreement to Abzena has the potential to reach over $300 million, comprising licence fees and milestone payments. In addition, Abzena would also receive royalties on sales of approved products that incorporate the ThioBridge(TM) technology developed by its partner.
Dr John Burt, CEO of Abzena, commented:
"Abzena and the US biopharmaceutical company has enjoyed an ongoing collaborative research programme to evaluate ThioBridge(TM) up until now. The collaboration has allowed both parties to build a strong working relationship and to demonstrate the value of the ThioBridge(TM) technology in creating novel ADCs.
"Signing this extensive licence agreement for ThioBridge(TM) is further validation of our proprietary ADC technology and expertise. We look forward to continuing to work together with our partner for the development of novel ThioBridge(TM)|
|yup, prefer this thread, couldn't get the charts to work on mine so ignore that one, apologies. Well done all that are on board! Brokers have 93-£1 target price or intrinsic value price DYOR but IMO the outlook statement from them suggest more to come following further progression on licencing deals etc etc. Very tightly held, but positive news will see this further. GLA and am holding on...|
|when did you buy in keya ?|
|Well jog on then.......|
|On initial read of rns sounds positive $300million potential income..but then looked at share price last 12 months and fact this deal at lower value was announced 10 months ago and realised it's a classic loss making aim jam tomorrow story|
|License agreement, a step forward?|
|These new appointments need to get cracking and buy some shares.|
|Abzena CEO John Burt will be presenting at the Biotech Capital Conference in London on the 4th October. For further details and to register to attend, please click here: http://tinyurl.com/h55rtx8|
|new video at Proactive Investors is here: http://tinyurl.com/z5fjqs4|
|Someone must be in agreement with that "small' Buy.|
|Video interview with Julian Smith
Julian Smith, chief financial officer at drug developer and pharma services group Abzena (LON:ABZA), tells Proactive Investors the integration of two US companies acquired last year - PacificGMP and TCRS - is "progressing well".
Smith explains Abzena's integrated offering will help the company grow as customers are responding well.
He adds the licence agreement for ThioBridge is a "fantastic result for the group."|
|Woodfords stake now 23%|
my retirement fund
|Julian Smith, CFO, will be presenting to investors on the evening of the 18th February at the Proactive One2One biotech forum at the Chesterfield Hotel in Mayfair. To register to attend this event, please click here: http://tinyurl.com/z42o5am|